Hoth Expands Study of New Gel for EGFR Inhibitor Skin Toxicities
EGFR inhibitors are changing the way that many types of cancers are treated, but these drugs can cause adverse skin reactions, and Hoth Therapeutics, Inc. is hoping to show that their gel offers a potential solution.
The Skin of Color Society Reflects on 2023 and Offers Sneak Peek of 2024
The Skin of Color Society (SOCS) reports that 2023 was a year of exceptional progress for its mission to change the landscape for people with darker skin tones through research, education, mentorship, and advocacy. “As we usher in our 20th Anniversary milestone in 2024, we’re deeply grateful to so many SOCS leaders, members, supporters and collaborators who […]
FDA Clears Sofwave for Improving the Appearance of Skin Laxity on the Upper Arms
The U.S. Food and Drug Administration (FDA) has cleared Sofwave for the improvement of the appearance of skin laxity on the upper arms. In the US, Sofwave’s SUPERB (Synchronous Ultrasound Parallel Beam) technology is currently cleared for use as a non-invasive aesthetic treatment to improve facial lines and wrinkles, lift the eyebrow, and lift lax submental area […]
Study: AD, OCD Linked
People with atopic dermatitis (AD) may be up to three times as likely to develop obsessive-compulsive disorder (OCD), according to a research letter published in the December 2023 issue of the Archives of Dematological Research. When Yale School of Medicine researchers examined data from more than 214,000 participants in the All of Us Research Program, they found that people […]
Is an Acne Vaccine on the Horizon?
A new vaccine targeting a variant of hyaluronidase may reduce acne-related inflammation, according to research in mice in Nature Communications. Researchers identified two variants of hyaluronidase, an enzyme produced by Cutibacterium acnes (C. acnes). One variant, called HylA, is strictly made by C. acnes that are associated with acne. The other variant (HylB) is made by C. acnes […]
JAK of All Trades, Master of Some? New Research Highlights Tissue-Specific Roles of JAK Signaling
Janus kinase (JAK) inhibitors are revolutionizing the way certain inflammatory diseases such as atopic dermatitis (AD) are being treated, but a more nuanced approach may be needed in modulating JAK activity for conditions like asthma. This is the main takeaway message from a new study in the December 21, 2023, issue of Cell. For the […]
Boston Dermatologist Wins Skin Ageing & Challenges Best Scientific Award 2023 for Research on Skin Biology, Aging
Professor Vladimir A. Botchkarev, MD, PhD, a distinguished Professor of Dermatology and Co-Director at the Boston University Center for Aging Research, has received the Skin Ageing & Challenges Best Scientific Award for 2023. The award, which was presented at The Skin Ageing & Challenges 2023 Conference in Lisbon, is for his paper titled “Skin Aging in Long-Lived Naked […]
TDD Alopecia Pipeline Watch: Enrollment Complete for Equillium’s Phase 2 Study of EQ101 in AA
Equillium, Inc. has completed enrollment of the EQ101 Phase 2 study in alopecia areata, the Company reports. EQ101 is a first-in-class, selective, tri-specific inhibitor of interleukin (IL)-2, IL-9 and IL-15. The study enrolled 36 patients, of which 13, or 36%, had severe alopecia areata. The study remains ongoing, but EQ101 has been well tolerated over the […]
Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
Evolus, Inc. has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom (U.K.) and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name Estyme (pronounced “esteem”) fillers in 2025. This marks the second […]
Study: The Number of New Dermatology Drugs Approved by the FDA Is on the Rise
The number of new dermatologic drug approvals by the U.S. Food and Drug Administration (FDA) increased between 2012 and 2022 compared with prior decades, according to a research letter in JAMA Dermatology. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high […]